Arcellx announces pricing of initial public offering

Gaithersburg, md., feb. 04, 2022 (globe newswire) -- arcellx, inc. (nasdaq: aclx), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced the pricing of its initial public offering of 8,250,000 shares of common stock at a public offering price of $15.00 per share. the gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by arcellx, are expected to be approximately $123.8 million. in addition, arcellx has granted the underwriters a 30-day option to purchase up to an additional 1,237,500 shares of common stock at the initial public offering price, less underwriting discounts and commissions. all of the shares of common stock are being offered by arcellx. arcellx's common stock is expected to begin trading on the nasdaq global select market on february 4, 2022, under the ticker symbol “aclx.” the offering is expected to close on february 8, 2022, subject to the satisfaction of customary closing conditions.
ACLX Ratings Summary
ACLX Quant Ranking